Milan, le 19 janvier 2009 - Recordati annonce l'acquisition de Herbacos-Bofarma, société pharmaceutique tchèque dont le siège est à Pardubice. Cette acquisition, d'environ 19 millions d'euros, a été financée par les liquidités existantes.
Herbacos-Bofarma est une société pharmaceutique renommée présente sur les marchés tchèque et slovaque avec un portefeuille important de médicaments de diverses classes thérapeutiques, composé notamment de produits antalgiques, anti-inflammatoires et dermatologiques. Les marques de la société occupent une forte position sur certains segments de marché. Herbacos-Bofarma emploie 100 personnes, parmi lesquelles un réseau de vente et marketing de 35 personnes s'est fait connaître auprès des pharmaciens et des médecins. The company is very solid financially. Sales have increased consistently over recent years and in 2008 are around E 12 million. The company's ebitda margin is in line with that of the group.
"The acquisition of Herbacos-Bofarma represents a further step in our strategy of building a direct presence in Central and Eastern Europe", declared Giovanni Recordati, Chairman and CEO. "The economies of the Czech Republic and Slovakia are among the most dynamic in this area and the relative pharmaceutical markets are among the most evolved. Herbacos-Bofarma, with a market share of around 2% in volumes, is well positioned to act as a platform for launching the new products in our pipeline in the Czech and Slovak markets."
Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, isin IT 0003828271),with a total staff of over 2,400, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the emerging markets of Eastern Europe. A European field force of over 1,300 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research TEAM has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2007 was E 628.4 million, operating income was E 131.5 million and net income was E 84.9 million.
For further information:
Recordati website: www.recordati.com
Claudio Rossetti (Echo Comunicazione d'Impresa)
Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
VIA M. CIVITALI, 1 - 20148 MILANO, ITALY - TEL (39) 02 48787.1 - FAX (39) 02 40073747
Ce communiqué de presse est diffusé par Hugin. L'émetteur est seul responsable du contenu de ce communiqué.